Overview

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects switched from previous treatment with either Pramipexole or Ropinirole.

Phase:

Phase 4

Details

Lead Sponsor:

UCB BIOSCIENCES GmbH

Collaborator:

Otsuka Pharmaceutical Co., Ltd.

Treatments:

N 0437
Pramipexole
Ropinirole
Rotigotine